Ozagrel has been used in trials studying the treatment of Dry Eye Syndromes. It is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.Reference standards of Ozagrel API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => Ozagrel Sodium (JP 0171) [catalogue_number] => PA JP0171 [category_ids] => ,152, [chemical_name] => [weight] => NA [form] => NA [cas] => NA [pslug] => ozagrel-sodium-jp-0171-pajp0171 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA JP0171
CAS :
Molecular Formula : NA
Molecular Weight : NA
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....